« Previous
Next »
Journal of Cardiac Failure
Volume 11, Issue 8
, Pages 602-606
, October 2005
High Prevalence of Microalbuminuria in Chronic Heart Failure Patients
References
- Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–1782
- Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–426
- . Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61:2165–2175
- Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249:519–526
- . Enhanced urinary excretion of albumin in congestive heart failure: effect of ACE-inhibition. Scand J Clin Lab Invest. 1992;52:193–199
- . Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: the case for AT1 receptor antagonist. J Am Soc Nephrol. 2004;15(Suppl 1):S71–S76
- . Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
- . Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase?. Nephrol Dial Transplant. 2003;18:10–13
- Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107:1284–1290
- Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921–927
- . Albuminuria and the permselective properties of the glomerulus in cardiac failure. Kidney Int. 1980;17:507–514
- . Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol. 2000;11:1882–1888
- Radial artery flow-mediated dilatation in heart failure patients: effects of pharmacological and nonpharmacological treatment. Hypertension. 2001;38:1451–1455
- Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation. 2000;102:351–356
- Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study. J Am Coll Cardiol. 2003;41:2022–2028
- A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study. Am Heart J. 2001;141:439–446
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253–259
- . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878
- . Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730–1736
- . Albumin to creatinine ratio: a screening test with limitations. Am J Kidney Dis. 2002;39:1183–1189
F.W. Asselbergs is a research fellow of the Netherlands Heart Foundation (2003T010). D.J. van Veldhuisen is an established investigator of the Netherlands Heart Foundation.
PII: S1071-9164(05)00238-1
doi: 10.1016/j.cardfail.2005.05.007
© 2005 Elsevier Inc. All rights reserved.
« Previous
Next »
Journal of Cardiac Failure
Volume 11, Issue 8
, Pages 602-606
, October 2005
